Literature DB >> 33497471

Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a single-center experience.

Pietro Maria Lombardi1, Michele Mazzola1, Pietro Achilli1, Maria Costanza Aquilano2, Paolo De Martini1, Annabella Curaba3, Monica Gualtierotti1, Camillo L Bertoglio1, Carmelo Magistro1, Giovanni Ferrari1.   

Abstract

BACKGROUND AND
OBJECTIVE: Perioperative chemotherapy (PC) with radical surgery represents the gold standard of treatment for resectable advanced gastric cancer (GC). The prognostic value of pathological tumor regression grade (TRG) induced by neoadjuvant chemotherapy (NACT) is not clearly established. This study aimed to investigate the correlation between TRG and survival in GC.
METHODS: Patients affected by advanced GC undergoing PC and radical surgery were considered. TRG was assessed for each patient according to Becker's grading system. The correlation between TRG and survival was investigated.
RESULTS: One-hundred patients were selected; 25 showed a good response (GR) (TRG 1a/1b), while 75 had a poor response (PR) (TRG 2/3) to NACT. GR patients showed better disease-free survival (DFS) (52 vs. 19 months, p < .001) and disease-specific survival (DSS) (57 vs. 25 months, p < .0001) when compared to PR patients. On univariate analysis, TRG, lymph node ratio (LNR), tumor size, grading, and post-neoadjuvant therapy TNM stage were significantly correlated with survival. On multivariate analysis, TRG, LNR and tumor size were independent prognostic factors for DFS and DSS.
CONCLUSIONS: TRG, LNR, and tumor size are independent prognostic factors for DFS and DSS in patients with advanced GC undergoing NACT.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  gastric cancer; neoadjuvant chemotherapy; survival; tumor regression grade; ypTNM

Year:  2021        PMID: 33497471     DOI: 10.1002/jso.26391

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  Open versus laparoscopic gastrectomy for advanced gastric cancer: a propensity score matching analysis of survival in a western population-on behalf of the Italian Research Group for Gastric Cancer.

Authors:  Pietro Maria Lombardi; D Bernasconi; G L Baiocchi; M Berselli; A Biondi; C Castoro; M Catarci; M Degiuli; U Fumagalli Romario; S Giacopuzzi; F Marchesi; D Marrelli; M Mazzola; S Molfino; S Olmi; S Rausei; F Rosa; R Rosati; F Roviello; S Santi; L Solaini; F Staderini; J Viganò; G Ferrari
Journal:  Gastric Cancer       Date:  2022-07-21       Impact factor: 7.701

2.  Prognostic value and clinicopathological correlation of the tumor regression grade in neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study.

Authors:  Yi Wang; Handong Xu; Can Hu; Pengcheng Yu; Zhehan Bao; Yanqiang Zhang; Ruolan Zhang; Shengjie Zhang; Bing Li; Jean-Marie Aerts; Zhiyuan Xu; Xiangdong Cheng
Journal:  J Gastrointest Oncol       Date:  2022-06

3.  Pretreatment Contrast-Enhanced Computed Tomography Radiomics for Prediction of Pathological Regression Following Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer: A Preliminary Multicenter Study.

Authors:  Kun Xie; Yanfen Cui; Dafu Zhang; Weiyang He; Yinfu He; Depei Gao; Zhiping Zhang; Xingxiang Dong; Guangjun Yang; Youguo Dai; Zhenhui Li
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

4.  Quantitative Dynamic-Enhanced MRI and Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Prediction of the Pathological Response to Neoadjuvant Chemotherapy and the Prognosis in Locally Advanced Gastric Cancer.

Authors:  Yongjian Zhu; Zhichao Jiang; Bingzhi Wang; Ying Li; Jun Jiang; Yuxin Zhong; Sicong Wang; Liming Jiang
Journal:  Front Oncol       Date:  2022-03-29       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.